Wei-hua Tang
Endocrinology, Diabetes and Metabolism · 2008–2013
A researcher in the Science corpus: 3 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Endocrinology, Diabetes and Metabolism — 10 citations into it
- Surgery — 6 citations into it
Whom Wei-hua Tang trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from Wei-hua Tang's perspective
Ordered by how strongly the researchers Wei-hua Tang trusts endorse each paper. Same corpus, a different order for every researcher.
- Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study (British medical journal)
- Oral antihyperglycemic therapy for type 2 diabetes: scientific review. (Journal of the American Medical Association (JAMA))
- Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. (Journal of the American Medical Association (JAMA))
- Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins (British Journal of Nutrition)
- Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? (Atherosclerosis)
- Adipose tissue mass can be regulated through the vasculature (Proceedings of the National Academy of Sciences of the United States of America)
- Human C-reactive protein: expression, structure, and function. (Molecular Immunology)
- Is obesity an inflammatory condition? (Nutrition (Burbank, Los Angeles County, Calif.))
- Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. (Endocrinology)
- Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. (Journal of Clinical Endocrinology and Metabolism)
Their papers
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control (2013) — 657 citations
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise (2010) — 750 citations
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes (2008) — 690 citations